
    
      ROR-PH-302 is a 28-week multicenter, randomized, double-blind, placebo-controlled study.
      Subjects who meet entry criteria will be randomly allocated 2:1 to receive ralinepag or
      placebo, in addition to their PAH-specific background therapy, as applicable. The primary
      endpoint is change from Baseline in peak VO2 (assessed by CPET) at Week 28. All subjects who
      complete the study on study drug through Week 28 will have the option to receive ralinepag in
      an open-label extension (OLE) study.
    
  